AeroRx Therapeutics Raises $21M Series A

AeroRx Therapeutics, a clinical-stage biopharmaceutical company, has secured $21,000,000 in funding from investors. The company focuses on developing proprietary, combination products for nebulized delivery designed to improve the treatment of chronic respiratory diseases. This capital infusion marks a significant milestone for AeroRx as it advances its clinical pipeline. AeroRx's lead product candidate, inhaled AERO-007, is a nebulized LABA/LAMA fixed-dose combination drug currently in clinical development. It is being developed as a first-line maintenance therapy for chronic obstructive pulmonary disease (COPD) and aims to address the needs of patients who remain symptomatic or poorly served by existing treatments. A second program, AERO-111, is also in development as a nebulized LABA/LAMA/ICS triple therapy for patients requiring advanced treatment. The company's leadership team brings extensive expertise in aerosol drug delivery, clinical development, and regulatory strategy. The newly raised capital will be strategically deployed to advance the clinical development of AeroRx's product candidates, with a primary focus on progressing inhaled AERO-007 through its next stages. The funds will also support ongoing research and development efforts for AERO-111 and bolster the company's operational capabilities. This investment underscores investor confidence in AeroRx's innovative approach to addressing unmet needs in respiratory medicine. Headquartered in the Avalon BioVentures Accelerator in La Jolla, California, AeroRx Therapeutics is now well-positioned to accelerate its development programs. The company plans to leverage this investment to reach critical clinical milestones and further its mission of bringing effective, nebulized combination therapies to patients suffering from chronic respiratory conditions.